Company Name, Ticker, Customers, else..

Immunogen inc (NASDAQ: IMGN)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Immunogen Inc 's

Name: Immunogen Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IMGN Sales vs. its Competitors Q3 2023

Comparing the current results to its competitors, Immunogen Inc reported Revenue increase in the 3 quarter 2023 by 637.72 % year on year.
The sales growth was above Immunogen Inc 's competitors' average revenue growth of 112.24 %, achieved in the same quarter.

• List of IMGN Competitors

With a net margin of 27.11 % Immunogen Inc achieved higher profitability than its competitors.

• More on IMGN Profitability Comparisons

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Immunogen inc achieved net profit of $30.75 millions compared to a net loss of $-77.76 millions recorded in the same quarter a year ago.

<< IMGN Stock Performance Comparisons

<< See the full list of IMGN competitors

Overall company Market Share Q3 2023

Due to outstanding performance in Overall company, revenue grew by 637.72 % Immunogen inc improved its market share, to approximately 15.78 %. << More on IMGN Market Share.

*Market share is calculated based on total revenue.

IMGN's Stock Performance relative to its Competitors

Publicly Traded Peers of Immunogen inc

Zai Lab Limited
Share Performance

-10.52%

Over The Past 5 Days

Zai Lab Limited

Profile

Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.

More about Zai Lab Limited's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 26,986.077 mill.	$ 449.614 mill.	$ -188.213 mill.

Merus N v
Share Performance

+112.77%

This Year

Merus N v

Profile

Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.

More about Merus N v 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 6,810.807 mill.	$ 56.606 mill.	$ -381.135 mill.

Mirati Therapeutics Inc
Share Performance

-0.47%

Over The Past 5 Days

Mirati Therapeutics Inc

Profile

Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.

More about Mirati Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3,815.094 mill.	$ 38.191 mill.	$ -725.878 mill.

Mersana Therapeutics inc
Share Performance

+0.21%

This Year

Mersana Therapeutics inc

Profile

Mersana Therapeutics Inc's business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.

More about Mersana Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 145.286 mill.	$ 33.180 mill.	$ -70.081 mill.

Macrogenics Inc
Share Performance

+1.02%

This Quarter

Macrogenics Inc

Profile

Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.

More about Macrogenics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 251.198 mill.	$ 167.674 mill.	$ -14.592 mill.

63 more competitors available

Sources: Immunogen inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 11:02 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunogen inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.